Edit |   |
---|---|
Antigenic Specificity | CD279, Human (Spartalizumab biosimilar) |
Clone | Spartalizumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG4 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | n/a |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human CD279 Recombinant Antibody (Spartalizumab). Spartalizumab (INN, development code PDR001) is a monoclonal antibody that is being investigated for melanoma. This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials. |
Immunogen | n/a |
Other Names | Anti-CD279 Recombinant Antibody, Research Grade Spartalizumab, Anti-Human CD279 Recombinant Antibody(Spartalizumab), NPVPDR001, NVS240118, PDR001, Antibody Drug Analogues, Monoclonal Antibody, YR1475, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 1935694-88-4 |
Catalog # | YR1475 |
Price | please inquire |
Order / More Info | CD279, Human (Spartalizumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |